ROMVIMZA

Apr 03, 2026

Summary According to DelveInsight’s estimates, nearly 580,000 prevalent cases of TGCT were reported across the 7MM in 2025, with approximately 460,000 cases classified as localized TGCT and nearly 120,000 as diffuse TGCT; these subtypes differ notably in clinical presentation, recurrence rates, and overall dise...

Mar 03, 2025

Ono Pharmaceuticals received FDA approval on 14 February 2025 for vimseltinib, a treatment for tenosynovial giant cell tumor (TGCT), which will be sold under the brand name ROMVIMZA. This approval positions Ono in direct competition with fellow Japanese pharmaceutical company Daiichi Sankyo in the TGCT market. ...